IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10670611 B1

PDFFull Text
Date of Patent:
Jun. 02, 2020

Filed:

Nov. 03, 2014

Cardiovascular risk event prediction and uses thereof

Applicant:

Somalogic, Inc., Boulder, CO (US);

Inventors:

David Sterling, Boulder, CO (US);

Shintaro Kato, Boulder, CO (US);

Edward N. Brody, Boulder, CO (US);

Stephen A. Williams, Boulder, CO (US);

Assignee:

SomaLogic, Inc., Boulder, CO (US);

Attorney:

McNeill Baur PLLC

Primary Examiner:

Jane J Zara

Int. Cl.
CPC ...
G01N 33/68 (2006.01); G16B 20/00 (2019.01); G16B 40/00 (2019.01); C12Q 1/6883 (2018.01); G16H 50/20 (2018.01); G06N 7/00 (2006.01); G16H 50/30 (2018.01); G01N 33/53 (2006.01); G06Q 40/08 (2012.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C12Q 1/6883 (2013.01); G01N 33/5308 (2013.01); G01N 33/6887 (2013.01); G06N 7/005 (2013.01); G06Q 40/08 (2013.01); G16B 20/00 (2019.02); G16B 40/00 (2019.02); G16H 50/20 (2018.01); G16H 50/30 (2018.01); C12Q 2525/205 (2013.01); G01N 2333/4712 (2013.01); G01N 2333/4716 (2013.01); G01N 2333/515 (2013.01); G01N 2333/52 (2013.01); G01N 2333/521 (2013.01); G01N 2333/8121 (2013.01); G01N 2333/96486 (2013.01); G01N 2800/32 (2013.01); G01N 2800/50 (2013.01); G01N 2800/60 (2013.01);
Abstract

Methods and computer methods used to assess an individual for the prediction of risk of developing a Cardiovascular (CV) Event over a 1 to 5 year period are provided. The methods employ at least two biomarkers selected from MMP12, angiopoietin-2, complement C7, cardiac troponin I, angiopoietin-related protein 4, CCL18/PARC, alpha-1-antichymotrypsin complex, GDF11 and alpha-2-antiplasmin, or GDF11 in combination with FSTL3. The methods are particularly useful in predicting CV events in patients who suffer from coronary heart disease (CHD).

Find Patent Forward Citations

Loading…